Proprietary AI analyst is now available

Ambu Valuation Multiples

Discover Ambu's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Carl Zeiss Meditec, TransMedics, Double Medical Technology, Autobio Diagnostics and more.

Ambu Overview

About Ambu

Ambu AS provides medical technology solutions. The company’s business consists of research and development of new solutions, which are then manufactured, marketed, and sold. It operates in two verticals: Endoscopy Solutions and Anesthesia & Patient Monitoring, with the majority of revenue being generated from the Endoscopy Solutions business. Geographical segments include North America, Europe, and the Rest of the World.


Founded

1937

HQ

Denmark

Employees

5.0K

Website

ambu.com

Financials (LTM)

Revenue: $977M
EBITDA: $178M

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Ambu Financials

Ambu reported last 12-month revenue of $977M and EBITDA of $178M.

In the same LTM period, Ambu generated $591M in gross profit, $178M in EBITDA, and $94M in net income.

Revenue (LTM)


Ambu P&L

In the most recent fiscal year, Ambu reported revenue of $931M and EBITDA of $178M.

Ambu is profitable as of last fiscal year, with gross margin of 60%, EBITDA margin of 19%, and net margin of 10%.

See analyst estimates for Ambu
LTMLast FY202320242025202620272028
Revenue$977M$931M$760M$857M$948M
Gross Profit$591M$560M$437M$510M$572M
Gross Margin60%60%58%60%60%
EBITDA$178M$178M$98M$124M$178M
EBITDA Margin18%19%13%14%19%
EBIT Margin13%13%8%12%13%
Net Profit$94M$94M$29M$51M$94M
Net Margin10%10%4%6%10%

Financial data powered by Morningstar, Inc.

Ambu Stock Performance

Ambu has current market cap of $3B, and enterprise value of $3B.

Market Cap Evolution


Ambu's stock price is $10.03.

Ambu share price decreased by 4.7% in the last 30 days, and by 34.7% in the last year.

Ambu has an EPS (earnings per share) of $0.36.

See more trading valuation data for Ambu
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$3B1.0%-4.7%-7.2%-34.7%$0.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Ambu Valuation Multiples

Ambu trades at 2.7x EV/Revenue multiple, and 14.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Ambu

EV / Revenue (LTM)


Ambu Financial Valuation Multiples

As of June 10, 2026, Ambu has market cap of $3B and EV of $3B.

Ambu has a P/E ratio of 28.1x.

LTMLast FY202320242025202620272028
EV/Revenue2.7x2.8x3.5x3.1x2.8x
EV/EBITDA14.7x14.7x26.8x21.3x14.7x
EV/EBIT21.2x21.7x43.9x25.0x21.5x
EV/Gross Profit4.4x4.7x6.0x5.1x4.6x
P/E28.1x28.2x92.9x52.3x28.1x
EV/FCF35.3x41.8x61.9x34.4x39.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Ambu Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Ambu Margins & Growth Rates

Ambu grew revenue by 7% but EBITDA decreased by 0% in the last fiscal year.

In the most recent fiscal year, Ambu reported gross margin of 60%, EBITDA margin of 19%, and net margin of 10%.

See estimated margins and future growth rates for Ambu

Ambu Margins

Last FY202420252026202720282029
Gross Margin60%60%60%61%
EBITDA Margin19%14%19%18%
EBIT Margin13%12%13%13%
Net Margin10%6%10%10%
FCF Margin7%9%7%8%

Ambu Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%13%11%8%
Gross Profit Growth8%17%12%9%
EBITDA Growth(0%)26%44%6%
EBIT Growth3%75%16%11%
Net Profit Growth1%78%86%10%
FCF Growth27%80%(12%)26%

Data powered by FactSet, Inc. and Morningstar, Inc.

Ambu Operational KPIs

Ambu's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Ambu's Rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ambu's Rule of X is 39% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Ambu
LTMLast FY202320242025202620272028
Rule of 4029%27%---
Bessemer Rule of X44%39%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue30%30%31%29%30%
G&A Expenses to Revenue12%12%12%12%12%
R&D Expenses to Revenue6%6%6%6%6%
Opex to Revenue-47%50%47%46%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Carl Zeiss Meditec1.1x1.1x6.5x7.4x
TransMedics4.9x4.5x18.3x18.8x
Double Medical Technology6.0x5.6x16.6x14.0x
Autobio Diagnostics3.8x3.7x9.4x9.6x
Sinbon Electronics2.5x2.3x16.8x18.4x
Tecan Group2.1x2.1x13.5x13.5x
MGI Tech6.2x5.9x107.2x74.3x
Establishment Labs12.1x10.8x(179.3x)(9436.9x)

This data is available for Pro users. Sign up to see all Ambu competitors and their valuation data.

Start Free Trial

Acquisitions by Ambu

Ambu has acquired 2 companies to date.

Last acquisition by Ambu was on October 25th 2017. Ambu acquired invendo medical for $243M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Ambu

invendo medical
ETView Medical
Description
invendo medical is a Germany-based developer of disposable, flexible endoscopy products for gastroenterology procedures. The company targets improvements in patient compliance to boost procedure volumes by prioritizing maneuverability over optical enhancements alone. invendo medical distributes single-use endoscopes designed for enhanced usability in diagnostic and therapeutic applications across global markets.
-
HQ CountryGermanyIsrael
HQ City
Kissing
Misgav
Deal Date25 Oct 201723 Jun 2016
Valuation$243M$16M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Ambu acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Ambu

When was Ambu founded?Ambu was founded in 1937.
Where is Ambu headquartered?Ambu is headquartered in Denmark.
How many employees does Ambu have?As of today, Ambu has over 5K employees.
Is Ambu publicly listed?Yes, Ambu is a public company listed on Nasdaq Copenhagen.
What is the stock symbol of Ambu?Ambu trades under AMBU B ticker.
When did Ambu go public?Ambu went public in 1993.
Who are competitors of Ambu?Ambu main competitors include Carl Zeiss Meditec, TransMedics, Double Medical Technology, Autobio Diagnostics, Sinbon Electronics, Tecan Group, MGI Tech, Establishment Labs, Insight Lifetech, Integer Holdings.
What is the current market cap of Ambu?Ambu's current market cap is $3B.
What is the current revenue of Ambu?Ambu's last 12 months revenue is $977M.
What is the current revenue growth of Ambu?Ambu revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of Ambu?Current revenue multiple of Ambu is 2.7x.
What is the current EBITDA of Ambu?Ambu's last 12 months EBITDA is $178M.
What is Ambu's EBITDA margin?Ambu's last 12 months EBITDA margin is 18%.
What is the current EV/EBITDA multiple of Ambu?Current EBITDA multiple of Ambu is 14.7x.
What is the current FCF of Ambu?Ambu's last 12 months FCF is $74M.
What is Ambu's FCF margin?Ambu's last 12 months FCF margin is 8%.
What is the current EV/FCF multiple of Ambu?Current FCF multiple of Ambu is 35.3x.
How many companies Ambu has acquired to date?As of June 2026, Ambu has acquired 2 companies.
What was the largest acquisition by Ambu?$243M acquisition of invendo medical on 25th October 2017 was the largest M&A Ambu has done to date.
What companies Ambu acquired?Ambu acquired invendo medical and ETView Medical.
In how many companies Ambu has invested to date?Ambu hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Ambu

Lists including Ambu

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial